Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027209 · ClinicalTrials.gov registry record · Phase 2
Hormone Replacement in Menopausal Women With Epilepsy
A Phase 2 study of Epilepsy and Menopause, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT00027209 is a Phase 2 study of Epilepsy and Menopause that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 125 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00027209, a Phase 2 study of Epilepsy and Menopause, has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate the effect of synthetic hormone replacement therapy on anti-seizure medication levels, menopausal symptom relief, and seizure frequency and safety in menopausal women with epilepsy.
Interventions
- DRUG prempro
Study Locations (1)
New York
- New York Presbyterian Hospital-Weill Medical College of Cornell University, Comprehensive Epilepsy Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027209
The ClinicalTrials.gov registry entry for NCT00027209 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (87% lower). The listed sponsor is National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which prempro is the first listed.
NCT00027209 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00027209 about?
NCT00027209 is a clinical study titled "Hormone Replacement in Menopausal Women With Epilepsy". The goal of this study is to evaluate the effect of synthetic hormone replacement therapy on anti-seizure medication levels, menopausal symptom relief, and seizure frequency and safety in menopausal women with epilepsy.
What is the current status of trial NCT00027209?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants.
What conditions does trial NCT00027209 study?
This clinical trial studies the following conditions: Epilepsy, Menopause.
What interventions are being tested in trial NCT00027209?
The interventions under investigation include: prempro (DRUG).
Who is sponsoring clinical trial NCT00027209?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00027209 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Pediatric Epilepsy Study in Subjects 1-24 Months
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.